Skip to main content

Table 1 Patients inclusion and exclusion criteria of the study.

From: A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

INCLUSION CRITERIA

EXCLUSION CRITERIA

≥18 years

Patients with prior history of type 1 or type 2 diabetes

Newly diagnosed NODAT defined by pathologic OGTT (2 h, 75 mg glucose): glucose ≥200 mg/dL

Body mass index (BMI) > 40 kg/m 2

- Pregnancy

Renal transplantation (deceased or living donor) and treatment with the standard immunosuppressionat our center, consisting of a triple therapy with tacrolimusor cyclosporine A, mycophenolatemofetil, and prednisone

Severe renal impairment (GFR < 30 mL/min./1.73 m2)

Stable graft function for more than 6 months post transplant

Severe liver impairment (ASAT/ALAT levels over threefold elevated compared to reference values)

Informed consent of the patient

Severe blood glucose elevation with the need for insulin therapy or